Download PDF
Zeitschrift für Phytotherapie 2014; 35(01): 6-11
DOI: 10.1055/s-0033-1349782
Forschung
Nephrologie
© Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Phytotherapie bei Glomerulonephritis und weiteren zur Niereninsuffizienz führenden Nierenerkrankungen

Übersicht über die klinische Forschung – Teil 1
Rainer Nowack
Subject Editor:
Further Information

Publication History

Publication Date:
06 March 2014 (online)

    Permissions and Reprints

Zusammenfassung

Glomerulonephritiden sind eine wichtige Ursache für terminale Niereninsuffizienz und Dialysepflichtigkeit. Sie werden nach klinischem Verlauf, Histologie und Pathogenese zu Entitäten klassifiziert, für die jeweils unterschiedliche Therapiekonzepte gelten. Da bei den meisten GN eine autoimmunologische Pathogenese vorliegt, sprechen sie auf Immunsuppressiva an – allerdings bei vielfach noch unbefriedigendem Erfolg und dem Preis hoher Toxizität. Während aus der europäischen Tradition der Phytotherapie keine Therapien für diese Erkrankungen hervorgegangen sind, gibt es interessante Phytotherapeutika innerhalb der chinesischen Medizin. Beginnend mit diesem Beitrag zu Astragalus membranaceus werden in den folgenden Beiträgen die wichtigsten Phytotherapeutika für diese Erkrankungen vorgestellt und kritisch bewertet.

Summary

Phytotherapy for glomerulonephritis and related kidney diseases

Clinical research overview – part 1
Glomerulonephritides are an important cause of terminal renal disease and dialysis dependency. They are classified in entities according to anamnesis, histology and pathogenesis based on different treatment concepts. Due to the presence of an auto-immunological pathogenesis for most GNs, they respond to immunosuppressive drugs, but often with unsatisfactory success and high rate of toxicity. Whilst there is little evidence of therapy for these diseases from the European traditional herbal medicine, there are interesting phytotherapeutics from Chinese medicine. Starting with this article on Astragalus membranaceus, other subsequent ones will present and critically assess the most important phytotherapeutics for these diseases.

Schlüsselwörter

Glomerulonephritis - membranöse Glomerulonephritis - IgA-Nephropathie - Astragalus membranaceus - Astragalosid IV

Key words

Glomerulonephritis - membranous Glomerulonephritis - IgA nephropathy - Astragalus membranaceus - astragaloside IV
 

  • LITERATUR

  • 1 Stratta P, Canavese C, Sandri L et al. The concept of ‘glomerulonephritis’. Am J Nephrol 1999; 19: 83-91
    CrossrefPubMedGoogle Scholar
  • 2 Eddy AA, López-Guisa JM, Okamura DM, Yamaguchi I. Investigating mechanisms of chronic kidney disease in mouse models. Pediatr Nephrol 2012; 27: 1233-1247
    CrossrefPubMedGoogle Scholar
  • 3 Babacan T, Onat AM, Pehlivan Y et al. Successful treatment of refractory adult Still’s disease and membranous glomerulonephritis with infliximab. Clin Rheumatol 2010; 29: 423-426
    CrossrefPubMedGoogle Scholar
  • 4 Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48: 1600-1604
    CrossrefPubMedGoogle Scholar
  • 5 Polanco N, Gutiérrez E, Covarsí A et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704
    CrossrefPubMedGoogle Scholar
  • 6 Dikow R, Quentmeier P, Schwenger V et al. Optimal blood pressure control versus additional immunosuppressive therapy in idiopathic membranous nephropathy – a retrospective analysis. Clin Nephrol 2009; 72: 366-372
    PubMedGoogle Scholar
  • 7 Eitner F, Ackermann D, Hilgers RD, Floege J. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. J Nephrol 2008; 21: 284-289
    PubMedGoogle Scholar
  • 8 Javaid B, Quigg RJ. Treatment of glomerulonephritis: Will we ever have options other than steroids and cytotoxics?. Kidney Int 2005; 67: 1692-1703
    CrossrefPubMedGoogle Scholar
  • 9 De Santo NG, Aliotta A, de Santo RM, Aliotta G. Josephus Andreas Jacobus Plenck – a forerunner of modern diuretic therapy. . Nephron 2002; 92: 22-31
    CrossrefPubMedGoogle Scholar
  • 10 Zhang ZZ, Liang XM, Zhang Q, Lu PZ. Characterization and recognition key components in Astragalus membranaceus [Article in Chinese]. Yao Xue Xue Bao 2001; 36: 523-527
    PubMedGoogle Scholar
  • 11 Xu M, Yin J, Xie L et al. Pharmacokinetics and tolerance of total astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers. Phytomedicine 2013; 20: 1105-1111
    CrossrefPubMedGoogle Scholar
  • 12 Bensky D, Gamble A. Chinese herbal medicine. Materia Medica. Seattle: Eastland Press; 1993
    Google Scholar
  • 13 Zhao XZ. Effects of Astragalus membranaceus and Tripterygium hypoglancum on natural killer cell activity of peripheral blood mononuclear cells in systemic lupus erythematosus. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1992; 12: 679-671
    PubMedGoogle Scholar
  • 14 Wang YP, Li XY, Song CQ, Hu ZB. Effect of astragaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice. Acta Pharmacol Sin 2002; 23: 263-266
    PubMedGoogle Scholar
  • 15 Su L, Chen XJ, Hu JD, Zhou SG, Mao JC. Comparisons between different doses of Astragalus membranaceus and Salvia miltiorrhiza in rats proteinuria. Chin J New Drugs Clin Rem 2000; 19: 205-208
    PubMedGoogle Scholar
  • 16 Wang HY, Li JZ, Pan JS, Zou WZ, Li XM, Zhang YK et al. The effect of Astragalus and Angelica on nephrotic syndrome and its mechanisms of action. J Peking Univ Health Sci 2002; 34: 542-552
    PubMedGoogle Scholar
  • 17 Wang H, Li J, Yu L et al. Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis. Life Sci 2004; 74: 1645-1658
    CrossrefPubMedGoogle Scholar
  • 18 Border WA, Okuda S, Languino LR et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990; 346: 371-374
    CrossrefPubMedGoogle Scholar
  • 19 Ding W, Li JZ, Zou WZ, Wang HY. Astragalus and Angelica reduce TGFB1 expression in nephrotic rats induced by puromycin aminonucleoside. Chin J Nephrol 1998; 14: 229-232
    PubMedGoogle Scholar
  • 20 Zuo C, Xie XS, Quiu HY et al.. Astragalus mongholicus ameliorates renal fibrosis by modulating HGF and TGF-beta in rats with unilateral ureteral obstruction. Z Zheijiang Univ Sci B 2009; 10: 380-390
    PubMedGoogle Scholar
  • 21 Zheng R, Deng Y, Chen Y et al.. Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway. Phytother Res 2012; 26: 892-898
    CrossrefPubMedGoogle Scholar
  • 22 Shi JF, Zhu HW, Zhang C et al. Therapeutic effect of Astragalus on patients with chronic glomerulonephritis. Acta University Medicinalis Secondae Shanghai 2002; 22: 245-248
    PubMedGoogle Scholar
  • 23 Chen QY. The effect of Radix astragali in treating patients with proteinuria. Lishizhen Med Materia Medica Res 2001; 12: 1016-1017
    PubMedGoogle Scholar
  • 24 Bao XH, Zhou ZL, Li L et al.. Observation of Astragalus injection combined with the angiotensin converting enzyme inhibitor (ACEI) on patients with nephrogenous albuminuria. Shi Yong Yi Yao Za Zhi 2003; 19: 132-133
    PubMedGoogle Scholar
  • 25 Shi P, Lin WM, Fu ZG. Clinical research of Radix astragali injection on nephrotic syndrome. Zhong Guo Xin Yi Xue 2003; 2: 30-31
    PubMedGoogle Scholar
  • 26 Xue JF, Guo QZ, Song JG, Li YY. Clinical analysis on treating primary nephrotic syndrome with Astragali and Ligustrazine. J Inner Mongolia University for Nationalities 2002; 17: 151-152
    PubMedGoogle Scholar
  • 27 Ahmed MS, Hou SH, Battaglia MC et al.. Treatment of idiopathic membranous nephropathy with the herb Astragalus membranaceus . Am J Kidney Dis 2007; 50: 1028-1032
    CrossrefPubMedGoogle Scholar
  • 28 Zhao YQ, Li GQ, Guo CX, Lian X. Evaluation the effect of TNF-alpha, RBC immunologic function and improvement renal function by Astragalus root in patients with chronic renal failure. J Mudanjiang Med Coll 2000; 21: 5-6
    PubMedGoogle Scholar
  • 29 Yang HR, Ma JC, Wang XP et al. The effect of Astragalus on immunity in patients with chronic renal failure. Zhong Xi Yi Jie He Shi Yong Lin Chuang Ji Jiu 1997; 4: 404-405
    PubMedGoogle Scholar
  • 30 Yu SY, Ouyang HT, Yang JY et al.. Subchronic toxicity studies of Radix Astragali extract in rats and dogs. J Ethnopharmacol 2007; 110: 352-355
    CrossrefPubMedGoogle Scholar
  • 31 Jiangbo Z, Xuying W, Yuping Z et al. Effect of astragaloside IV on the embryo-fetal development of Sprague-Dawley rats and New Zealand White rabbits. J Appl Toxicol 2009; 29: 381-385
    CrossrefPubMedGoogle Scholar
  • 32 Sinclair S. Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. Altern Med Rev 1998; 3: 338-344
    PubMedGoogle Scholar
  • 33 Kim W, Kim SH, Park SK, Chang MS. Astragalus membranaceus ameliorates reproductive toxicity induced by cyclophosphamide in male mice. Phytother Res 2012; 26: 1418-1421
    CrossrefPubMedGoogle Scholar